Related Experiment Videos
Estriol binding in uterine corpus cancer and in normal uterine tissues
1Department of Obstetrics and Gynecology, Gifu University School of Medicine, Japan.
Abstract:
1. The specific bindings of estriol (E3) and estradiol-17 beta (E2) to their specific receptors were investigated in endometrial carcinoma from 7 patients and normal tissues from their respective organs or from other patients. 2. In both cytosolic and KCl-extracted fractions from them, specific binding sites for E3 and E2 were detected, demonstrating the presence of their separate receptors in human uterus-associated tissues. 3. In certain cases (6 cases) of well-differentiated adenocarcinoma, the ratio of concentration of E3 receptor to that of E2 receptor was almost equal to or higher than in other normal tissues. 4. These findings of unique localization of E3 receptor distribution may offer new insight into identification of endometrial carcinoma more likely to respond to hormonal influence or therapy.
Insights
Estrogen receptors for estriol (E3) and estradiol (E2) were found in endometrial carcinoma tissues. Unique E3 receptor distribution in well-differentiated adenocarcinoma may predict response to hormonal therapy.
Area of Science:
- Endocrinology
- Gynecologic Oncology
- Molecular Biology
Background:
- Endometrial carcinoma is a common gynecologic malignancy.
- Hormone receptor status is crucial for predicting treatment response in endometrial cancer.
- Estriol (E3) and estradiol-17 beta (E2) are key estrogens influencing endometrial tissue.
Purpose of the Study:
- To investigate the specific binding of estriol (E3) and estradiol-17 beta (E2) to their receptors in endometrial carcinoma.
- To compare the distribution and concentration of E3 and E2 receptors in cancerous versus normal endometrial tissues.
- To explore the potential of E3 receptor localization as a biomarker for hormonal therapy response.
Main Methods:
- Tissue samples from 7 endometrial carcinoma patients and normal controls were analyzed.
- Specific binding assays were performed on cytosolic and KCl-extracted fractions of the tissues.
- Quantification of estriol (E3) and estradiol-17 beta (E2) receptor concentrations was conducted.
Main Results:
- Specific binding sites for both E3 and E2 were detected in both cancerous and normal human uterus-associated tissues.
- In 6 cases of well-differentiated adenocarcinoma, the ratio of E3 receptor to E2 receptor concentration was comparable to or higher than in normal tissues.
- Unique localization patterns of E3 receptors were observed in certain endometrial carcinoma subtypes.
Conclusions:
- The presence of distinct estriol (E3) and estradiol-17 beta (E2) receptors in endometrial carcinoma is confirmed.
- The elevated E3 receptor to E2 receptor ratio in some well-differentiated adenocarcinomas suggests a potential role in hormonal responsiveness.
- These findings may aid in identifying endometrial cancers that are more likely to benefit from hormonal therapies.